U.S. Markets open in 2 hrs 51 mins

Bionano Genomics, Inc. (BNGO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5444+0.0080 (+1.49%)
At close: 4:00PM EDT

0.5465 0.00 (0.39%)
Before hours: 5:45AM EDT

Sign in to post a message.
  • T
    TruTrader
    SAN DIEGO, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Dr. Erich Jarvis, a Howard Hughes Medical Institute investigator at the Rockefeller University and Chair of the Vertebrate Genome Project (VGP), is bringing his expertise in comparative genomics to the COVID-19 Host Genome SV Consortium as a co-principal investigator. The consortium, founded by Dr. Ravindra Kolhe at Augusta University, is centered around the analysis with Saphyr of structural variants (SVs) in the human genome that predispose to or protect against COVID-19. Identifying such variants in the genome can lead to the development of novel drugs, the repurposing of existing drugs for COVID-19, the development of targeted vaccines and importantly, the identification of risk markers that allow better triaging of patients who need certain treatment or early access to vaccines.

    Dr. Jarvis brings to the consortium a unique and powerful approach to understanding host response genetics called comparative genomics, in which genomes of different species with and without certain traits are compared to reveal the variants responsible for the traits of interest. In the case of COVID-19 response, the genomes of animals that are believed to be sensitive to SARS-CoV-2 infection will be compared to genomes of species presumed to be immune to infection or disease. The non-human animal species that were susceptible to SARS-CoV-2 infection to be included in the study are the Chinese horseshoe bat, a natural reservoir for the virus; the Chinese pangolin, an alternative reservoir; the clouded leopard, an animal that tested positive for SARS-CoV-2 infection in the Bronx Zoo; and four domestic species that are believed to be vulnerable: the sheep, Arabian camel, horse and Chinese hamster. For the human arm of the study, the Jarvis team will analyze the genomes of ten patients who were hospitalized and/or died from COVID-19. The genomes of ten individuals who did not get sick after exposure will function as controls along with those of more than one hundred vertebrate species assembled by the VGP and presumed to be resistant to infection.
    Analysis by comparative genomics requires complete genome assemblies for the species to be analyzed, and those assemblies have to be as accurate and complete as possible. The genome assembly team of the VGP has developed and optimized a pipeline utilizing long-read sequencing, Bionano optical maps, and a method called Hi-C to build reference-quality genomes.

    Data generated with Bionano’s Saphyr system are essential for these assemblies because Bionano data provide a level of structural accuracy required to achieve complete and accurate assemblies, as was demonstrated in a previously announced publication that showed Saphyr’s contribution to the first ever telomere-to-telomere assembly of a complete human X chromosome.

    Typical genome analysis studies use short-read sequencing technologies and have limits because they miss rare variants, cannot analyze parts of the genome that are absent from the reference and they suffer from incorrect alignments to structural variants and incomplete assemblies with gaps in important regions, such as complex, repetitive immune genes. Long-read sequencing data combined with structural variation data generated by Saphyr can build the high-quality genomes needed for the VGP, and provide the genome structural variation data needed to investigate the COVID-19 response across species. The comparative genomics approach to studying the various animal species and human patient genomes allows for a detailed characterization of conserved genetic elements, and may identify elements crucial to vulnerability or protection from infection. Dr. Jarvis and the VGP intend to include further focus on the ACE2 gene, which enables the virus to infect the cell, the MHC region that plays a crucial part in the immune response to the virus and analyze the rest of the genome as well. Many immune gene regions have been incompletely assembled in most draft genomes, making it impossible to do this type of comparative genomics analysis until complete reference quality genomes are available for each species. The high-quality genomes are the only available method to analyze point-mutations and structural variations together.

    Erik Holmlin, PhD, CEO of Bionano Genomics added: “The SARS-CoV-2 pandemic has turned the world on its side this year, leading to a concerted global effort by researchers to better understand how to properly combat this pandemic and who is most at risk of developing severe COVID-19. We believe the most effective way to develop and steer effective treatment is to better understand the genomic basis for COVID-19 susceptibility. This belief in part prompted the creation of the COVID-19 Host Genome SV Consortium, using Saphyr as the core technology to find the structural variants that predispose to or protect against disease.
    Bullish
  • P
    Prateek
    Just buy, hold and forget. Invest only that much amount which you can lose without breaking a sweat (worst case scenarios) .
    Hold for next 5 years... This is going to $100.
    Elon musk in an interview said three things will rule the next decade : space, genome analysis and autonomous transportation.
  • T
    TruTrader
    Huge down day across the board, Except for $BNGO which is up 1.7+% so far with 10 minutes to close!
    Bullish
  • i
    ioan
    On Twitter : Bionano Genomics is #hiring a Staff Electrical Engineer, responsible for the design, development, and production-release of new instruments!
    Bullish
  • I
    Ivanaldo
    Dr. Erich Jarvis at Rockefeller University is bringing comparative #genomics to the COVID-19 Host #Genome SV Consortium. He is using #Saphyr to discover why certain animals & patients are susceptible to #COVID19 while others are resistant.
  • F
    Frans
    It’s such simple math. In June they had 116 machines sold and 86 installed. They sold another 40+ till August. One machine can do 3-7 tests a day (before the software updatethat will be more now already) $700 on average per kit. And they keep selling machines and now will start lease of machines. The lease will boost the selling of kits.
    And the institutions buying and leasing the machine don’t do that to test once a month...
    They will sell a lot of kits and that will increase revenue rapidly.
    My best guess is that the amount of sold test figures will show why the CEO is so happy to announce the the ER.
    And the extra money raised will give them a production boost to lease machines creating fast revenue growth.

    Competition is far behind on this technology.

    Only shorts can keep this stock down but not for long
  • K
    Kevin
    I left a phone message with Bionano’s Sven Bocklandt, PhD, Director of Scientific Affairs. I asked several questions. As of today, everyone knows the technology is revolutionary and outperforms any competition by far. We keep getting reaffirmation about Saphyr from numerous press releases validating its superiority. The information is anazing, very appreciated, and is supported by a cornucopia of peer reviewed journal articles...

    ...we are also receiving positive financial reports, with future ones expected to be ever better.

    However, we are not being informed of some of the important details...

    How many research labs have the technology in place?

    How many bought the whole system?

    How many are leasing it?

    Who is placing orders?

    Are any companies using it for COVID research?

    What does it cost to lease/own?

    Are there orders being filled right now and/or are systems currently being built to fill orders?

    How many field operators are installing systems and training users as we speak?

    Are systems being financed?

    etc., etc., etc...

    I think these are some of the things investors want to know...at least I do!!!!
    Bullish
  • J
    John
    This stock boggles my mind...lol....do investors realize that if this guy actually finds the variant for covid 19 that determines serious vs mild symptoms EVERY HOSPITAL IN THE WORLD will be leasing or buying a saphyr
  • g
    ghita
    Repost from @TruTrader ( thanks for your work and involvement- you do a lot for us all! ) :

    HUGE NEWS!!! Received a response to my email sent to Ashley Robinson (Managing Director - LifeSci Advisors, LLC). They/she is listed as the investor contact for BioNano Genomics if you look on their website! The date for compliance in order to not be delisted from NASDAQ is in all actuality currently June 2021. I was also told & I quote, "We believe that during that time, we can achieve compliance in an ORGANIC fashion." She used the same word that I have been using "Organically". NO REVSE SPIT IN OUR FUTURE!
  • T
    TruTrader
    History of optical mapping:In 1993, Schwartz et al. [25] demonstrated the use of optical mapping by constructing ordered restriction maps of Saccharomyces cerevisiae chromosomes. First, the stained and stretched DNA molecules were fixed in agarose gel and then nicked by a selected restriction enzyme. Next, specialized fluorescence microscopy was used to observe and record the specific patterns of single-molecule DNA restriction fragments. However, it was later found that the thickness of agarose gel can affect image capture by scattering light and attenuating signals.

    To solve this problem, in 1995 Cai et al. [30] and Meng et al. [31] fixed DNA molecules on glass surfaces that had been treated with specific chemicals. Consequently, the DNA stretch rate was improved to 60% of its contour length, compared with 30% on agarose [29]. The number of cut sites was also increased. To increase throughput, in 1998 Jing et al. [32] used the “fluid fixation” effect in their design of the first automated approach to generate restriction maps. The improvement of microfluidics and chemistries led to further advances in optical mapping, and in 2007, Jo et al. [33] reported a nanoslit approach that had higher accuracy and throughput in restriction map production.

    Throughout this time, companies such as OpGen, Bionano Genomics, and NABsys have invested intensively in single-molecule whole-genome mapping and have extended its application from microorganisms to more complex organisms. OpGen and Bionano Genomics have commercially released different platforms to produce optical maps, such as Argus from the former and Irys and Saphyr from the latter. However, with the acquisition of the Argus platform by BGI in 2011, OpGen’s optical mapping services were terminated. Bionano Genomics currently dominates the optical mapping market and continues to invest in technology development. Yet, given the pending release of the HD-mapping system from NABsys, it is likely that some of the Bionano Genomics market share will be taken by NABsys.

    2.1.1. OpGen optical mapping
    OpGen was licensed its technology from New York University and the University of Wisconsin and was the first company to commercialize optical mapping technology [34], represented by its release of the Argus platform and its accompanying analysis software, MapSolver [34], [35], [36]. OpGen applied the original restriction-based method for map construction to produce maps of 200 kb in length [10], [29], [36]. At first, Argus targeted simpler organisms, such as bacteria and yeast. Later, OpGen expanded its support to higher organisms across animals and plants, including humans, domestic goat and legume Medicago [34], [36], [37], [38]. A global alignment strategy was applied in the design of MapSolver to help detect complex genome rearrangements [36], [39]. However, with the sale of the Argus system, OpGen discontinued its optical mapping services, and its optical mapping market share was then assumed by its competitors.

    2.1.2. Bionano optical mapping
    Bionano Genomics is another optical mapping technology provider, originally named BionanoMatrix. The company rose to popularity in 2012 after the release of its massively parallel Irys platform, which applies nanochannel-array fluidics technology to produce optical maps [40]. This technology greatly enhances the throughput and the accuracy of molecule length estimation by use of a more uniform linearization [14], [40], and the use of nicking enzymes to create only single strand breaks preserve molecule contiguity more than OpGen technologies do. The Irys platform came bundled with the IrysView desktop application for data visualization and management. Bionano also provides its proprietary RefAligner for map alignment and Assembler for de novo map assembly, together with an IrysSolve Scripts package to assist data analysis. In 2016, two maps generated from the use of different nicking enzymes were added to the Irys workflow to complement the limited label density and increase map coverage. However, double strand breaks at “fragile sites” where two nicking sites locate closely (~400 bp) on opposite strands still hamper the contiguity of optical maps.

    Bionano recently developed Direct Label and Strain (DLS) technology to improve map contiguity to the chromosome-level [41]. The release of the DLS protocol was coupled with the new Saphyr platform, which has improved optics and throughput. DLE-1, the first enzyme in the DLS family, functions akin to a methyltransferase by labelling DNA without damaging it [29], [42]. DLE-1 eliminates the “fragile site” problem [43]. Currently, the Saphyr platform guarantees a production of 1300 Gb of raw data per flow-cell for human samples. The resolution of Bionano optical mapping has been increased up to 500 bp, and there have been attempts to develop algorithms to enable a resolution of 10 bp [40], [44]. Bionano has also updated

    https://www.sciencedirect.com/science/article/pii/S2001037020303500
    Recent advances in optical mapping have allowed the construction of improved genome assemblies with greater contiguity. Optical mapping also enables g…
    Recent advances in optical mapping have allowed the construction of improved genome assemblies with greater contiguity. Optical mapping also enables g…
    www.sciencedirect.com
    Bullish
  • T
    Tony
    Telling you guys BNGOs hitting all the my trade marks of a fierce competitor that should not be taken lightly.
    SPEED, ACCURACY, EASE OF USE, COST, AND PATENTED TECH. All characteristics labs and hospitals are looking for during this covid 19 economic downturn. BNGO will be gold standard globally in 2 years mark my WORDS.

    Bionano Genomics Releases Major Update to Its Suite of Software Tools That Simplifies Clinical Analysis, Reduces Time to Actionable Results and Makes Adoption by Clinical Labs Easier

    Reduced compute time, faster variant analysis, more comprehensive clinical annotation and streamlined workflow for non-human model genomes used in drug development improve Saphyr’s best in class structural variation analysis even further
    Bullish
  • T
    Tmoneeyy
    You will never see this stock this low again.
  • T
    TruTrader
    HIGHLIGHTS: Saphyr continues to increase its lead as the most powerful genome analysis platform for the detection of structural variants and copy number variations in human genomes and complex cancer samples. Saphyr’s unique ability to detect structural variants down to 1% allele fraction, genome-wide and unbiased, without enrichment or amplification and with the highest sensitivities and lowest false positives is unmatched by current short or long-read sequencing technologies. The new capabilities and improvements to our software further simplify and speed up the analysis and interpretation of clinical samples and we believe that these updates may help accelerate Saphyr’s adoption for Next-Generation Cytogenomics in the estimated 2,500 cytogenetics labs around the world.”
    Bullish
  • V
    Vik
    Stock
  • i
    ioan
    Bionano Genomics (NASDAQ: BNGO) announces the most significant update to its suite of software tools for data analysis since the launch of Saphyr in 2017. This version of Bionano Access contains over 100 new features and revisions designed to simplify and accelerate every step in the data analysis workflow and make Bionano data easier to interpret. The update is available now as a free download and will be included with Saphyr systems going forward. With these enhancements, it is expected that clinical labs that adopt Saphyr can more readily develop assays for a wide range of genetic diseases, including tests for pediatric neuro-developmental disorders, liquid biopsies for blood cancers like leukemias, lymphomas and multiple myeloma and tests for solid tumors as well.

    Current clinical standards of care for diagnostic testing in genetic disease and cancer are based on a series of medical guidelines that recommend structural variation (SV) analysis as first-tier testing. For genetic disease, chromosomal microarray (CMA) analysis is first tier and karyotyping (KT) and fluorescence in-situ hybridization (FISH) are used as reflex tests. Medical guidelines for testing in heme malignancies recommend using KT as first tier testing, alongside some rapid FISH assays and FISH panels, and recommend using CMA as reflex tests. In multiple publications and presentations, Saphyr has been shown to provide a single test that is 100% concordant with the testing methods currently recommended by these guidelines, which requires the use of three different technologies. To-date, this capability has not been shown by any other genome analysis platform. Saphyr has been shown to be significantly more sensitive and specific for SVs than next-generation sequencing (NGS) and to outperform long-read sequencing platforms from PacBio and Oxford Nanopore Technologies. This software updates further enhance Saphyr’s unique advantages for customers.

    Building on the success of Bionano EnFocus™ FSHD Analysis tools that automate the analysis of variants in a form of muscular dystrophy, this update is expected to be a key step forward in finalizing other EnFocus panels that automate analysis of variants in patients with genetic diseases, including autism spectrum disorder, developmental delay and repeat expansion disorders, patients with various heme malignancies, such as AML and CLL leukemias, and patients with solid tumors. This new version of the software makes it possible for Bionano EnFocus FSHD to run on the PC that ships with the Saphyr instrument without the need for cloud-based analysis or costly compute clusters. However, for analysis run on Bionano’s cloud-based Compute On Demand, the updated software is more efficient, expands capacity and reduces the analysis time, in some cases by threefold. For discovery research, like in cancer research where exceptional sensitivity is essential, cloud-based analysis now finishes in hours rather than in days.

    Mark Oldakowski, Chief Operating Officer of Bionano Genomics, who led the development of the software commented: “With the improvements to our analysis and visualization software announced today, Saphyr continues to increase its lead as the most powerful genome analysis platform for the detection of structural variants and copy number variations in human genomes and complex cancer samples. Saphyr’s unique ability to detect structural variants down to 1% allele fraction, genome-wide and unbiased, without enrichment or amplification and with the highest sensitivities and lowest false positives is unmatched by current short or long-read sequencing technologies. The new capabilities and improvements to our software further simplify and speed up the analysis and interpretation of clinical samples and we believe that these updates may help accelerate Saphyr’s adoption for Next-Generation Cytogenomics in the estimated 2,500 cytogenetics labs around the world.”
    Bullish
  • J
    Jonathan
    Let's go BNGO! Man if this thing starts to take off some of us will be happy campers...
  • T
    TruTrader
    HUGE NEWS!!! Received a response to my email sent to Ashley Robinson (Managing Director - LifeSci Advisors, LLC). They/she is listed as the investor contact for BioNano Genomics if you look on their website! The date for compliance in order to not be delisted from NASDAQ is in all actuality currently June 2021. I was also told & I quote, "We believe that during that time, we can achieve compliance in an ORGANIC fashion." She used the same word that I have been using "Organically". NO REVSE SPIT IN OUR FUTURE!
    Bullish
  • J
    Junior
    We will have an interesting week
    Bullish
  • E
    Eris
    Please no politics on this board unless it directly relates to our investment in this amazing technology. I think people already know who they are voting for. You are not going to change anyone's mind. Stay on topic. The conference is happening now!
    Bullish
  • K
    Kevin
    The reports of significant growth from Saphyr and Lineagen revenues are coming. It is simple common sense. Be patient, but know it is obviously coming, and $1 is very scant optimism. This is one of the greatest developments in history. In my humbly optimistic opinion, $75 is the mark, unless the deep state makes Bionano disappear. The Saphyr technology threatens to cure, which threatens the bottom line of many cash cow drugs and treatments that manage disease rather than cure it. However, those reaping the benefits of these cash cows are ready to transition to their next exploit, because they knew the technology was coming eventually, and we e are in a time when you can't stop progress anymore. Just like the powerful lobbyists behind non-renewable energy trying to squeeze out every last penny...we've known for 70+ years how dumb non-renewable energy is, and how inefficient and dirty combustion engines are, but money drove it to squeeze out every drop, and during all that timr, those making money always knew it would shift to smarter methods. So they've had 70+ years to squeeze out every penny and use profits to be perfectly situated to transition to EV and Hydrogen...

    Don't think the mefical industry and big pharmaceutical is any different. While new technologies have been suppressed for years, so big pharma can bleed people dry, they knew it would change. Information is insuppressable now...we are in the information age...so they have been planning to transition too.

    Saphyr will EXPLODE!!!!

    Nobel Peace Prize!!!!!!!
    Bullish